SARA VERDURA MARTINEZ

Projectes

Metabolism and Cancer

Ayuda de personal Miquel Servet

Codi oficial: CP20/00003 Start date:01/01/2021 Data fi: 31/12/2025 Investigador/a principal: ELISABET CUYÀS NAVARRO, JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: INSTITUTO DE SALUD CARLOS III Ajuda: 202,500 €

Metabolism and Cancer

Modificaciones postraduccionales de PD-L1 en la inmunoterapia del cáncer: Desarrollo de nuevas estrategias terapéuticas y fármaco-diagnósticas

Codi oficial: PI22/00297 Start date:01/01/2023 Data fi: 31/12/2025 Investigador/a principal: JAVIER ABEL MENÉNDEZ MENÉNDEZ, ELISABET CUYÀS NAVARRO Organisme finançador: INSTITUTO DE SALUD CARLOS III Ajuda: 123,420 €

Metabolism and Cancer

Ajuts per donar suport a les activitats dels grups de recerca de Catalunya (SGR-Cat 2021) - Metabolisme i càncer

Codi oficial: 2021 SGR 01507 Start date:01/01/2022 Data fi: 31/12/2024 Investigador/a principal: BEGOÑA MARTIN CASTILLO Organisme finançador: AGENCIA DE GESTIO D'AJUTS UNIV. I RECER. Ajuda: 24,000 €

Metabolism and Cancer

Un nuevo enfoque de la actividad ácido graso sintasa como sistema de procesamiento de información en la oncología de precisión funcional

Codi oficial: PID2022-141955OB-I00 Start date:17/10/2023 Data fi: 31/08/2026 Investigador/a principal: JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: MINISTERIO DE ECONOMIA Y COMPETITIVIDAD MINECO / Ajuda: 337,500 €

Publicacions

Precision Oncology in Girona , Metabolism and Cancer

Teixidor E, Sais E, Vásquez CA, Carbajal W, Hernández A, Sánchez G, Izquierdo A, Verdura S, Menéndez JA, Bosch-Barrera J

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Oncotarget, 2023, 14, 668-668 dx.doi.org/10.18632/oncotarget.28471

Metabolism and Cancer , Descriptive epidemiology, genetics and cancer prevention , Precision Oncology in Girona

Bosch-Barrera J, Roqué A, Teixidor E, Carmona-Garcia MC, Arbusà A, Brunet J, Martin-Castillo B, Cuyàs E, Verdura S, Menendez JA

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin

Pharmaceuticals, 2022, 15 dx.doi.org/10.3390/ph15010019

Metabolism and Cancer

Espinoza I, Yang L, Steen TV, Vellon L, Cuyàs E, Verdura S, Lau L, Menendez JA, Lupu R

Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin alpha(6)beta(1) drives endocrine resistance in breast cancer cells

Aging-Us, 2022, 14, 1200-1213 dx.doi.org/10.18632/aging.203882

Metabolism and Cancer

Yang, L, Vander Steen, T, Espinoza, I, Cuyas, E, Verdura, S, Menendez, JA, Lupu, R

Nuclear moonlighting of the secreted growth factor heregulin drives endocrine-resistant breast cancer independently of HER2/HER3 signaling

AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12, 2173-2188

Internal Medicine , Metabolism and Cancer

Llop-Hernández À, Verdura S, Cuyàs E, Menendez JA

Nutritional Niches of Cancer Therapy-Induced Senescent Cells

Nutrients, 2022, 14 dx.doi.org/10.3390/nu14173636

Metabolism and Cancer , Precision Oncology in Girona

Verdura S, Encinar JA, Fernández-Arroyo S, Joven J, Cuyàs E, Bosch-Barrera J, Menendez JA

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 dx.doi.org/10.3390/ijms23179986

Precision Oncology in Girona , Metabolism and Cancer

Verdura S, Encinar JA, Teixidor E, Segura-Carretero A, Micol V, Cuyàs E, Bosch-Barrera J, Menendez JA

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors

Cancers, 2022, 14 dx.doi.org/10.3390/cancers14246101

Metabolism and Cancer

Espinoza I, Kurapaty C, Park CH, Vander Steen T, Kleer CG, Wiley E, Rademaker A, Cuyàs E, Verdura S, Buxó M, Reynolds C, Menendez JA, Lupu R

Depletion of CCN1/CYR61 reduces triple-negative/basal-like breast cancer aggressiveness

AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12, 839-851

Metabolism and Cancer

Cuyàs E, Fernández-Arroyo S, Verdura S, Lupu R, Joven J, Menendez JA

Metabolomic and Mitochondrial Fingerprinting of the Epithelial-to-Mesenchymal Transition (EMT) in Non-Tumorigenic and Tumorigenic Human Breast Cells

Cancers, 2022, 14 dx.doi.org/10.3390/cancers14246214

Metabolism and Cancer

Tramonti A, Cuyàs E, Encinar JA, Pietzke M, Paone A, Verdura S, Arbusà A, Martin-Castillo B, Giardina G, Joven J, Vazquez A, Contestabile R, Cutruzzolà F, Menendez JA

Metformin Is a Pyridoxal-5 '-phosphate (PLP)-Competitive Inhibitor of SHMT2

Cancers, 2021, 13 dx.doi.org/10.3390/cancers13164009

12 3 4 5

Directori

Projectes

Publicacions

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin

Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin alpha(6)beta(1) drives endocrine resistance in breast cancer cells

Nuclear moonlighting of the secreted growth factor heregulin drives endocrine-resistant breast cancer independently of HER2/HER3 signaling

Nutritional Niches of Cancer Therapy-Induced Senescent Cells

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors

Depletion of CCN1/CYR61 reduces triple-negative/basal-like breast cancer aggressiveness

Metabolomic and Mitochondrial Fingerprinting of the Epithelial-to-Mesenchymal Transition (EMT) in Non-Tumorigenic and Tumorigenic Human Breast Cells

Metformin Is a Pyridoxal-5 '-phosphate (PLP)-Competitive Inhibitor of SHMT2

Formulari de contacte

About IDIBGI!